ES2252756T3 - Factores activadores de macrofagos derivados de la proteina de union a vitamina d clonada. - Google Patents
Factores activadores de macrofagos derivados de la proteina de union a vitamina d clonada.Info
- Publication number
- ES2252756T3 ES2252756T3 ES96921279T ES96921279T ES2252756T3 ES 2252756 T3 ES2252756 T3 ES 2252756T3 ES 96921279 T ES96921279 T ES 96921279T ES 96921279 T ES96921279 T ES 96921279T ES 2252756 T3 ES2252756 T3 ES 2252756T3
- Authority
- ES
- Spain
- Prior art keywords
- protein
- cloned
- gcmaf
- cells
- domain iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 78
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 68
- 230000003213 activating effect Effects 0.000 title claims abstract description 27
- 229940088594 vitamin Drugs 0.000 title abstract description 3
- 229930003231 vitamin Natural products 0.000 title abstract description 3
- 235000013343 vitamin Nutrition 0.000 title abstract description 3
- 239000011782 vitamin Substances 0.000 title abstract description 3
- 150000003722 vitamin derivatives Chemical class 0.000 title abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 57
- 201000011510 cancer Diseases 0.000 claims abstract description 34
- 239000013598 vector Substances 0.000 claims abstract description 33
- 241000701447 unidentified baculovirus Species 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 15
- 210000002540 macrophage Anatomy 0.000 claims description 77
- 210000004027 cell Anatomy 0.000 claims description 70
- 241000700605 Viruses Species 0.000 claims description 24
- 241000238631 Hexapoda Species 0.000 claims description 18
- 239000002299 complementary DNA Substances 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 8
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000005348 Neuraminidase Human genes 0.000 claims description 7
- 108010006232 Neuraminidase Proteins 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 6
- 108091008324 binding proteins Proteins 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 claims description 5
- 102000003960 Ligases Human genes 0.000 claims description 5
- 108090000364 Ligases Proteins 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 208000016861 hereditary angioedema type 3 Diseases 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 102000028728 vitamin binding proteins Human genes 0.000 claims description 2
- 108091009357 vitamin binding proteins Proteins 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims 3
- 235000005282 vitamin D3 Nutrition 0.000 claims 3
- 239000011647 vitamin D3 Substances 0.000 claims 3
- 229940021056 vitamin d3 Drugs 0.000 claims 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 22
- 210000002966 serum Anatomy 0.000 abstract description 13
- 238000002649 immunization Methods 0.000 abstract description 9
- 230000003053 immunization Effects 0.000 abstract description 9
- 208000001132 Osteoporosis Diseases 0.000 abstract description 8
- 238000002255 vaccination Methods 0.000 abstract description 5
- 208000031886 HIV Infections Diseases 0.000 abstract description 3
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 238000011275 oncology therapy Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 41
- 230000000694 effects Effects 0.000 description 41
- 241000699666 Mus <mouse, genus> Species 0.000 description 34
- 230000004913 activation Effects 0.000 description 30
- 102100031317 Alpha-N-acetylgalactosaminidase Human genes 0.000 description 28
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 20
- 210000002381 plasma Anatomy 0.000 description 20
- 239000002243 precursor Substances 0.000 description 15
- 210000002997 osteoclast Anatomy 0.000 description 14
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 230000000242 pagocytic effect Effects 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 210000000628 antibody-producing cell Anatomy 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000001539 phagocyte Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 102000007436 Macrophage-Activating Factors Human genes 0.000 description 4
- 108010086123 Macrophage-Activating Factors Proteins 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 3
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000256251 Spodoptera frugiperda Species 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 2
- 241001131785 Escherichia coli HB101 Species 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101000956004 Homo sapiens Vitamin D-binding protein Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 101001045218 Homo sapiens Peroxisomal multifunctional enzyme type 2 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010043183 Teething Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102100038611 Vitamin D-binding protein Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000052021 human DBP Human genes 0.000 description 1
- 102000051433 human GC Human genes 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/478,121 US5620846A (en) | 1995-06-07 | 1995-06-07 | Diagnostic and prognostic indices for cancer and aids |
| US478121 | 1995-06-07 | ||
| US618485 | 1996-03-19 | ||
| US08/618,485 US6410269B1 (en) | 1995-06-07 | 1996-03-19 | Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2252756T3 true ES2252756T3 (es) | 2006-05-16 |
Family
ID=27045792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96921279T Expired - Lifetime ES2252756T3 (es) | 1995-06-07 | 1996-06-05 | Factores activadores de macrofagos derivados de la proteina de union a vitamina d clonada. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6410269B1 (enExample) |
| EP (3) | EP1340815A3 (enExample) |
| JP (1) | JPH11511962A (enExample) |
| CN (2) | CN1174097C (enExample) |
| AT (1) | ATE307885T1 (enExample) |
| AU (1) | AU6253596A (enExample) |
| BR (1) | BR9609072A (enExample) |
| CA (1) | CA2223940A1 (enExample) |
| DE (2) | DE69635346D1 (enExample) |
| ES (1) | ES2252756T3 (enExample) |
| NO (1) | NO323155B1 (enExample) |
| WO (1) | WO1996040903A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985545A (en) * | 1996-03-19 | 1999-11-16 | Yamamoto; Nobuto | Diagnostic and prognostic ELISA assays of serum α-N-acetylgalactosaminidase for AIDS |
| CA2409759A1 (en) * | 2000-05-09 | 2001-11-15 | Children's Medical Center Corporation | Method and composition for the treatment of angiogenesis |
| WO2002021133A2 (en) * | 2000-09-07 | 2002-03-14 | The Brigham And Women's Hospital, Inc. | Methods of detecting cancer based on prostasin |
| US20050009120A1 (en) * | 2000-09-07 | 2005-01-13 | The Brigham And Women's Hospital, Inc. | Methods of detecting ovarian cancer based on osteopontin |
| WO2002058589A2 (en) * | 2000-11-09 | 2002-08-01 | Northeastern Ohio Universities College Of Medicine | Agents and methods for promoting bone growth |
| US20020164664A1 (en) * | 2000-11-30 | 2002-11-07 | Matritech, Inc. | Detection and treatment of prostate cancer |
| US7112408B2 (en) * | 2001-06-08 | 2006-09-26 | The Brigham And Women's Hospital, Inc. | Detection of ovarian cancer based upon alpha-haptoglobin levels |
| US6806355B2 (en) | 2001-08-14 | 2004-10-19 | Statens Serum Institut | Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product |
| US7288383B2 (en) * | 2003-01-15 | 2007-10-30 | The Brigham And Women's Hospital, Inc. | Eosinophil-derived neurotoxin as a marker for ovarian cancer |
| WO2005087793A2 (en) * | 2004-02-05 | 2005-09-22 | The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Immunostimulatory compositions and uses thereof |
| US20050186577A1 (en) * | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| WO2006063028A2 (en) * | 2004-12-07 | 2006-06-15 | The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Immunostimulatory compositions and uses thereof |
| US8496942B2 (en) | 2006-12-13 | 2013-07-30 | Susavion Biosciences, Inc. | Therapeutic peptides and uses thereof |
| US8460697B2 (en) | 2006-12-13 | 2013-06-11 | Susavion Biosciences, Inc. | Pro-angiogenic peptides and uses thereof |
| USRE46425E1 (en) | 2006-12-13 | 2017-06-06 | Susavion Biosciences, Inc. | Pro-angiogenic peptides and uses thereof |
| US7811995B2 (en) | 2006-12-13 | 2010-10-12 | Susavion Biosciences, Inc. | Therapeutic and diagnostic peptides |
| US7838497B2 (en) | 2006-12-13 | 2010-11-23 | Susavion Biosciences, Inc. | Pro-angiogenic peptides |
| IN2012DN02200A (enExample) * | 2009-08-22 | 2015-08-21 | Charles Knezevich | |
| EP2612921B1 (en) | 2010-09-03 | 2016-11-02 | Morita Pharmaceutical Ind., Ltd. | Method for production of novel degalactosylated gc globulin |
| CN103547280B (zh) * | 2011-04-07 | 2017-06-09 | 艾弗兰纳特有限公司 | 用于药物组合物的巨噬细胞活化因子 |
| EP2561879A1 (en) | 2011-08-23 | 2013-02-27 | Protea Biopharma N.V. | Macrophage activating factor for use in the treatment of chronic fatigue syndrome (CFS) and CFS-related diseases and disorders |
| WO2013130953A2 (en) * | 2012-03-01 | 2013-09-06 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
| EP2687264A1 (en) | 2012-07-17 | 2014-01-22 | Protea Biopharma N.V. | Macrophage Activating Factor for treatment of endometriosis |
| WO2014113641A1 (en) * | 2013-01-18 | 2014-07-24 | Kline Ellis | Selective glycosidase regimen for immune programming and treatment of cancer |
| CN105530950A (zh) * | 2013-06-09 | 2016-04-27 | 艾弗兰纳特有限公司 | 包含Gc-巨噬细胞活化因子的组合物及其用途 |
| AT518622A1 (de) * | 2016-04-21 | 2017-11-15 | Hg Pharma Gmbh | Dimerer Komplex aus selektiv deglycosyliertem Vitamin D bindenden Protein (GcMAF) und Cholecalciferol (Calciol) und Verfahren zu dessen Herstellung |
| EP3725883B1 (en) * | 2017-12-15 | 2024-01-24 | Foundation for Biomedical Research and Innovation at Kobe | Method for producing active gcmaf |
| JPWO2022124331A1 (enExample) | 2020-12-08 | 2022-06-16 | ||
| CN118325844B (zh) * | 2023-09-07 | 2025-01-03 | 武汉奥科博泰生物科技有限公司 | 识别N-乙酰-β-D-氨基葡萄糖苷酶的单克隆抗体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5326749A (en) | 1989-11-20 | 1994-07-05 | Nobuto Yamamoto | Macrophage activating factor from vitamin D binding protein |
| US5177002A (en) * | 1989-11-20 | 1993-01-05 | Nobuto Yamamoto | In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor |
| US5177001A (en) | 1989-11-20 | 1993-01-05 | Nobuto Yamamoto | In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor |
| US5516657A (en) * | 1992-05-11 | 1996-05-14 | Cambridge Biotech Corporation | Baculovirus vectors for expression of secretory and membrane-bound proteins |
| US5652352A (en) * | 1994-03-31 | 1997-07-29 | Amgen Inc. | Afamin: a human serum albumin-like gene |
-
1996
- 1996-03-19 US US08/618,485 patent/US6410269B1/en not_active Expired - Lifetime
- 1996-06-05 AU AU62535/96A patent/AU6253596A/en not_active Abandoned
- 1996-06-05 ES ES96921279T patent/ES2252756T3/es not_active Expired - Lifetime
- 1996-06-05 EP EP03075633A patent/EP1340815A3/en not_active Withdrawn
- 1996-06-05 WO PCT/US1996/008867 patent/WO1996040903A1/en not_active Ceased
- 1996-06-05 DE DE69635346A patent/DE69635346D1/de not_active Expired - Lifetime
- 1996-06-05 EP EP04076092A patent/EP1443112A3/en not_active Withdrawn
- 1996-06-05 BR BR9609072-3A patent/BR9609072A/pt not_active Application Discontinuation
- 1996-06-05 EP EP96921279A patent/EP0837932B1/en not_active Expired - Lifetime
- 1996-06-05 JP JP9501337A patent/JPH11511962A/ja not_active Ceased
- 1996-06-05 CN CNB961958081A patent/CN1174097C/zh not_active Expired - Fee Related
- 1996-06-05 CA CA002223940A patent/CA2223940A1/en not_active Abandoned
- 1996-06-05 CN CNA031480365A patent/CN1510147A/zh active Pending
- 1996-06-05 AT AT96921279T patent/ATE307885T1/de not_active IP Right Cessation
- 1996-06-05 DE DE69635346T patent/DE69635346T4/de not_active Expired - Lifetime
-
1997
- 1997-01-06 US US08/779,729 patent/US5712104A/en not_active Expired - Lifetime
- 1997-12-08 NO NO19975771A patent/NO323155B1/no not_active IP Right Cessation
-
2001
- 2001-04-05 US US09/826,463 patent/US20020055140A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO975771L (no) | 1998-01-30 |
| NO975771D0 (no) | 1997-12-08 |
| US6410269B1 (en) | 2002-06-25 |
| EP0837932A1 (en) | 1998-04-29 |
| CN1510147A (zh) | 2004-07-07 |
| DE69635346D1 (de) | 2005-12-01 |
| CN1191567A (zh) | 1998-08-26 |
| CA2223940A1 (en) | 1996-12-19 |
| EP0837932B1 (en) | 2005-10-26 |
| DE69635346T4 (de) | 2007-11-08 |
| EP1340815A2 (en) | 2003-09-03 |
| EP0837932A4 (en) | 2001-02-28 |
| US5712104A (en) | 1998-01-27 |
| AU6253596A (en) | 1996-12-30 |
| BR9609072A (pt) | 2000-10-24 |
| WO1996040903A1 (en) | 1996-12-19 |
| US20020055140A1 (en) | 2002-05-09 |
| JPH11511962A (ja) | 1999-10-19 |
| DE69635346T2 (de) | 2006-07-27 |
| EP1340815A3 (en) | 2003-09-17 |
| CN1174097C (zh) | 2004-11-03 |
| ATE307885T1 (de) | 2005-11-15 |
| NO323155B1 (no) | 2007-01-08 |
| EP1443112A2 (en) | 2004-08-04 |
| EP1443112A3 (en) | 2004-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2252756T3 (es) | Factores activadores de macrofagos derivados de la proteina de union a vitamina d clonada. | |
| ES2254403T3 (es) | Produccion de muteinas recombinantes de factor de coagulacion sanguinea viii en lineas de celulas humanas. | |
| ES2234032T3 (es) | Terapia para la deficiencia de alfa-galactosidasa a. | |
| EA018084B1 (ru) | Виросомоподобные везикулы, содержащие антигены, производные от gp41, и их применение | |
| EA005579B1 (ru) | Пептиды, полученные из казеина, и их применение в терапии | |
| EA038250B1 (ru) | Рекомбинантный белок gl цитомегаловируса с мутацией в сайте распознавания протеазой, которая уменьшает протеазное расщепление | |
| PT1385538E (pt) | Vacinas quiméricas compreendendo o domínio luminal de lamp-1 ou lamp-2 | |
| Ruiz-Argüello et al. | Effect of proteolytic processing at two distinct sites on shape and aggregation of an anchorless fusion protein of human respiratory syncytial virus and fate of the intervening segment | |
| JP2021509809A (ja) | コロナウイルス感染症の治療または予防に使用するためのプロテアーゼ活性を有するペプチド | |
| JP2002507546A (ja) | 角質細胞増殖因子−２の治療的使用 | |
| US20160367653A1 (en) | Vault Immunotherapy | |
| EP0538273A1 (en) | Alveolar surfactant proteins | |
| US20200318137A1 (en) | Trail-secreting mesenchymal stem cells and use thereof to treat brain tumors | |
| WO2006082763A1 (ja) | Ｄａｎｃｅまたはその発現を増強する因子による弾性線維再生の方法 | |
| US6800479B2 (en) | Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them | |
| US20060014143A1 (en) | Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis | |
| RU2198218C2 (ru) | СПОСОБ КЛОНИРОВАНИЯ СВЯЗЫВАЮЩЕГО ВИТАМИН D3 БЕЛКА (БЕЛКА Gc), СПОСОБ ПОЛУЧЕНИЯ КЛОНИРОВАННОГО ФАКТОРА АКТИВАЦИИ МАКРОФАГОВ, ФАКТОР АКТИВАЦИИ МАКРОФАГОВ (ВАРИАНТЫ), АДЪЮВАНТ (ВАРИАНТЫ), КЛОНИРОВАННЫЙ СВЯЗЫВАЮЩИЙ ВИТАМИН D3 БЕЛОК (Gc-БЕЛОК), КЛОНИРОВАННЫЙ ДОМЕН III СВЯЗЫВАЮЩЕГО ВИТАМИН D3 БЕЛКА (ВАРИАНТЫ) | |
| JPH03178995A (ja) | 蛋白質およびその製造法 | |
| EA025275B1 (ru) | Способ, терапевтическая композиция, вакцинная комбинация и набор для терапевтического или профилактического лечения вич | |
| ES2228115T3 (es) | Material biologico para la preparacion de composiciones farmaceuticas destinadas al tratamiento de mamiferos. | |
| FI104424B (fi) | Menetelmä onkostatiini M -mutantin valmistamiseksi | |
| NZ506695A (en) | Utilization of cd137 in order to promote the profileration of peripheral monocytes | |
| KR20230112691A (ko) | 바이러스 감염을 치료하기 위한 방법 및 조성물 | |
| EP2083855B1 (en) | Measles virus nucleoprotein for treating atherosclerosis | |
| WO2024061239A1 (zh) | 用于预防或治疗冠状病毒感染的融合蛋白、Spike蛋白纳米颗粒及其应用 |